Tianda Pharmaceuticals
Market Cap
HK$415.0m
Last Updated
2021/04/11 10:12 UTC
Data Sources
Company Financials
Executive Summary
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. More Details
Risk Analysis
Snowflake Analysis
Mediocre balance sheet and overvalued.
Share Price & News
How has Tianda Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 455 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 455's weekly volatility (10%) has been stable over the past year.
Market Performance
7 Day Return
-10.6%
455
0.8%
HK Pharmaceuticals
-1.1%
HK Market
1 Year Return
27.0%
455
21.2%
HK Pharmaceuticals
28.6%
HK Market
Return vs Industry: 455 exceeded the Hong Kong Pharmaceuticals industry which returned 21.2% over the past year.
Return vs Market: 455 underperformed the Hong Kong Market which returned 28.6% over the past year.
Shareholder returns
| 455 | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.6% | 0.8% | -1.1% |
| 30 Day | 14.9% | 0.7% | -1.8% |
| 90 Day | 44.0% | 10.0% | 3.4% |
| 1 Year | 28.0%27.0% | 23.0%21.2% | 33.5%28.6% |
| 3 Year | -33.9%-35.7% | -14.3%-19.1% | 4.0%-6.9% |
| 5 Year | -59.0%-61.0% | 79.2%62.4% | 48.7%23.7% |
Long-Term Price Volatility Vs. Market
How volatile is Tianda Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
How Much Did Tianda Pharmaceuticals'(HKG:455) Shareholders Earn From Share Price Movements Over The Last Five Years?3 months ago | Simply Wall St
Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?7 months ago | Simply Wall St
Tianda Pharmaceuticals (HKG:455) Has A Pretty Healthy Balance SheetValuation
Is Tianda Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
0.56x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 455 (HK$0.19) is trading above our estimate of fair value (HK$0.02)
Significantly Below Fair Value: 455 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 455 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.
PE vs Market: 455 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 455's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 455 is good value based on its PB Ratio (0.6x) compared to the HK Pharmaceuticals industry average (1.3x).
Future Growth
How is Tianda Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianda Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Tianda Pharmaceuticals performed over the past 5 years?
-27.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 455 is currently unprofitable.
Growing Profit Margin: 455 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 455 is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare 455's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 455 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 455 has a negative Return on Equity (-1.84%), as it is currently unprofitable.
Financial Health
How is Tianda Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 455's short term assets (HK$542.4M) exceed its short term liabilities (HK$144.0M).
Long Term Liabilities: 455's short term assets (HK$542.4M) exceed its long term liabilities (HK$82.3M).
Debt to Equity History and Analysis
Debt Level: 455's debt to equity ratio (8.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 455's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 455's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 455's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is Tianda Pharmaceuticals's current dividend yield, its reliability and sustainability?
0.67%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 455's dividend (0.67%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.96%).
High Dividend: 455's dividend (0.67%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).
Stability and Growth of Payments
Stable Dividend: 455 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 455 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 455 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 455's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.6yrs
Average board tenure
CEO
Alan Fang (51 yo)
4.17yrs
Tenure
HK$60,000
Compensation
Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...
Board Members
Experienced Board: 455's board of directors are considered experienced (9.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Tianda Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Tianda Pharmaceuticals Limited
- Ticker: 455
- Exchange: SEHK
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$414.958m
- Shares outstanding: 2.15b
- Website: https://www.tiandapharma.com
Number of Employees
Location
- Tianda Pharmaceuticals Limited
- CITIC Tower
- 24th Floor
- Central
- Hong Kong
Listings
Biography
Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hon...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 10:12 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.